Diagnostic Tests and Management Strategies for Sickle Cell Disease

Diagnostic Tests

• The diagnosis of sickle cell disease requires a comprehensive hemoglobinopathy screen using high-performance liquid chromatography, capillary electrophoresis, mass spectrometry, or gel electrophoresis, which should be confirmed by a second test such as solubility testing or electrophoresis on agar in citrate buffer 1, 2
• Newborn screening programs can detect sickle cell disease where available 3
• Hemoglobin electrophoresis confirms the presence of hemoglobin S 3
• A positive sickle solubility test should not be used in isolation as it doesn't differentiate between heterozygous, compound heterozygous, or homozygous states 2

Additional Laboratory Evaluation

• Complete blood count to assess for normocytic normochromic anemia 4, 3
• Reticulocyte count to evaluate bone marrow response to hemolysis 4, 3
• Markers of hemolysis including bilirubin (total and direct) 4
• Renal function tests (BUN, creatinine) to evaluate for kidney injury 4
• Liver function tests (AST, ALT, alkaline phosphatase) to assess hepatobiliary involvement 4
• Coagulation studies (PT, PTT) to evaluate for coagulopathy 4
• Urinalysis to check for hematuria, proteinuria, or signs of urinary tract infection 4

Specialized Testing Based on Clinical Presentation

• Arterial blood gas for patients with suspected acute chest syndrome 4
• Blood cultures if infection is suspected 4
• Transcranial Doppler studies for children to assess stroke risk 5, 4
• Echocardiography for patients with signs or symptoms suggestive of pulmonary hypertension 5
• Pulmonary function testing for patients with respiratory symptoms 6
• Sleep studies for patients with symptoms of sleep-disordered breathing 6

Management Strategies

Acute Complications Management

• Pain management with analgesics, adequate hydration, and in severe cases, parenteral opioids 3
• Prompt treatment of infections due to increased susceptibility from splenic dysfunction 3
• Specific management for acute chest syndrome, including oxygen therapy, antibiotics, and possibly exchange transfusion 1, 6
• Management of stroke with immediate neurological evaluation and appropriate interventions 3
• Treatment of priapism, which can occur in children and adolescents 3

Chronic Complications Management

• Regular screening with transcranial Doppler for children to assess stroke risk 5
• Echocardiography for patients with signs or symptoms of pulmonary hypertension 5
• Combination therapy with hydroxyurea and erythropoiesis-stimulating agents for worsening anemia associated with chronic kidney disease 6
• Indefinite anticoagulation for adults with first unprovoked VTE or recurrent provoked VTE 6
• Defined periods of anticoagulation (3-6 months) for adults with first surgically or nonsurgically provoked VTE 6

Important Clinical Considerations

• Baseline laboratory values should be known for comparison, as many patients with SCD have chronic abnormalities 4
• Laboratory abnormalities should be interpreted in the context of the patient's clinical presentation 4
• Avoid relying solely on hemoglobin levels to determine the need for transfusion - consider the patient's baseline hemoglobin and clinical status 4
• Monitor for complications of treatment, such as fluid overload or transfusion reactions 4
• Clearly communicate the diagnosis of SCD on laboratory request forms to ensure appropriate processing and interpretation 4

Common Pitfalls in Diagnosis and Management

• Using sickle solubility test alone for diagnosis, which can give false negative results in neonates or heavily transfused patients 2

Diagnostic Approach for Sickle Cell Disease

Extended Red Cell Antigen Profiling

• Obtain an extended red cell antigen profile by genotype or serology at the earliest opportunity, optimally before the first transfusion, including at minimum K, Jk^a/Jk^b, Fy^a/Fy^b, and other relevant antigens, as recommended by the American Society of Hematology, with genotyping preferred over serologic phenotyping due to increased accuracy 7
• Genotyping is preferred over serologic phenotyping because it provides additional antigen information and increased accuracy, particularly for C antigen determination and Fy^b antigen matching, according to the National Heart, Lung, and Blood Institute 8
• A serologic phenotype may be inaccurate if the patient has been transfused in the last 3 months, highlighting the importance of genotyping in patients with a history of transfusion, as noted by the American College of Medical Genetics 7

Reticulocyte Count in Sickle Cell Disease

Role as a Baseline and Predictive Marker

• The bone marrow's ongoing response to baseline anemia is reflected by the reticulocyte count, which represents chronic hemolysis rather than acute crisis severity, according to the American Journal of Kidney Diseases 9
• Elevated reticulocyte count is a characteristic finding in sickle cell disease, reflecting the bone marrow's compensatory response to chronic hemolysis, as noted by The Journal of Urology 10

Important Clinical Context

• An inappropriately low reticulocyte count in the setting of worsening anemia warrants investigation for parvovirus B19 infection or other causes of marrow suppression, as reported by the American Journal of Kidney Diseases 9

Common Pitfalls

• Reticulocyte count should be interpreted alongside hemoglobin, bilirubin, and other hemolysis markers to assess bone marrow response, as recommended by Kidney International Supplements and the American Journal of Kidney Diseases 9, 11

Complications and Management Strategies in Sickle Cell Disease (Cited Evidence)

Acute Vaso‑occlusive Complication: Priapism

• In patients with sickle cell disease, priapism episodes lasting four hours or longer are associated with irreversible penile tissue damage. 12

Chronic Musculoskeletal Complications

• Avascular necrosis of the hip or shoulder joints is a recognized long‑term complication in individuals with sickle cell disease. 12

Ocular Complications

• Proliferative retinopathy, particularly in those with the HbSC genotype, can progress to retinal detachment if untreated. 12

Dermatologic Complications

• Poorly healing skin ulcers, especially around the ankles, frequently occur as chronic complications of sickle cell disease. 12

Neuropsychological Impact

• Patients may experience neuropsychological decline that impairs school or work performance, even in the absence of clinically evident stroke. 12

Hematologic Management: Iron Therapy

• Iron supplementation does not improve anemia in sickle cell disease and therefore should not be used routinely. 12
• Therapeutic iron should be withheld unless biochemical evidence of iron deficiency is present, due to the risk of lifelong iron overload from repeated red‑cell transfusions. 12

Gastrointestinal Complication: Gallstones

• Gallstone disease should be considered in children with sickle cell disease who present with right‑upper‑quadrant abdominal pain, recurrent vomiting, or worsening jaundice. 12